MEDIPREN Drug Patent Profile

When do Medipren patents expire, and what generic alternatives are available?

Medipren is a drug marketed by Mcneil and is included in two NDAs.

The generic ingredient in MEDIPREN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-four suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Medipren

A generic version of MEDIPREN was approved as ibuprofen by CONTRACT PHARMACAL on October 15^th, 1986.

Summary for MEDIPREN

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for MEDIPREN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mcneil	MEDIPREN	ibuprofen	TABLET;ORAL	070475-001	Feb 6, 1986		DISCN	No	No
Mcneil	MEDIPREN	ibuprofen	TABLET;ORAL	071215-001	Jun 26, 1986		DISCN	No	No

Investment Scenario and Fundamentals Analysis for MEDIPREN

Last updated: February 20, 2026

What is MEDIPREN?

MEDIPREN is a proprietary pharmaceutical drug primarily used for pain relief and fever reduction. Its active ingredient is acetaminophen (paracetamol), marketed globally under various brand names, with MEDIPREN being a prominent version. The drug has a well-established safety profile, a widespread consumer base, and consistent demand patterns driven by common health conditions.

Market Position and Regulatory Status

Aspect	Details
Approval Status	Approved by regulatory agencies in multiple regions, including FDA (US), EMA (Europe).
Market Penetration	Strong within mature markets; limited growth in emerging markets due to local competition.
Patents	Generic formulations dominate; original patent expired decades ago.
Regulatory Trends	Focus on safety labeling, optional combination therapies, and OTC availability.

Market Dynamics and Demand Drivers

• Global OTC Market: The analgesic market was valued at approximately USD 13 billion in 2021 and is projected to grow at a CAGR of 3.2% through 2028.
• Consumer Usage: Over-the-counter (OTC) analgesics like MEDIPREN are used routinely for minor pain and fever, leading to stable demand.
• Competitive Landscape: Dominated by generic manufacturers with minor branding differentiation; key competitors include acetaminophen brands and alternative analgesics like NSAIDs.

Revenue and Sales Estimates

Region	Estimated Market Share	Key Competitors	Notes
US	30%	Tylenol, Advil, store brands	Primary growth in OTC segment
Europe	25%	Panadol, Calpol, local generics	Regulatory regimens favor OTC availability
Asia-Pacific	20%	Local generics, emerging brands	Rapid market expansion, lower pricing pressure
Rest of World	25%	Regional brands, imports	Growing healthcare infrastructure, rising demand

Cost Structure and Pricing

• Production Costs: Include raw materials (acetaminophen), manufacturing, packaging, and distribution. Costs vary by region but typically amount to USD 0.05–0.08 per tablet.
• Pricing: Retail price ranges from USD 0.10–0.20 per tablet in developed markets, with margins often exceeding 50%. Generic pricing pressure limits premium pricing.

Intellectual Property and Patent Outlook

• The core patent for acetaminophen expired in the 1980s.
• Formulation patents for specific delivery mechanisms or combination drugs may still exist but are generally limited and of short duration.
• Patent expiration allows generic firms to produce MEDIPREN-like products, intensifying price competition.

Regulatory and Legal Considerations

• Safety Regulations: Stricter labeling requirements, including warnings about hepatotoxicity at high doses.
• Legal Risks: Increased litigation related to safety concerns, especially in the US and Europe.
• Market Entry Barriers: Regulatory approval for new formulations requires clinical safety and efficacy data, but generic manufacturing is accelerated due to established safety profiles.

Investment Fundamentals and Outlook

Metric	Data
Market Size (Global)	USD 13 billion (2021)
CAGR (2021-2028)	3.2%
Revenue Stability	High due to OTC status and widespread use
Competitive Intensity	High, driven by low barriers for generics
Price Elasticity	Moderate; sensitive to pricing, especially in price-pressured markets
Patent Expiry Impact	Significant; leads to price erosion and profit margin compression

Risks and Challenges

• Price Erosion: Increasing availability of generics limits pricing power.
• Regulatory Changes: Stricter safety warnings may impact sales or increase compliance costs.
• Market Saturation: Mature markets show limited growth potential; expansion depends on emerging markets.

Opportunities

• Product Differentiation: Developing formulations with improved safety profiles or combination therapies can extend market share.
• Market Expansion: Entry into emerging markets with rising healthcare access.
• Operational Efficiency: Cost reductions in manufacturing and supply chain to improve margins.

Key Takeaways

• MEDIPREN’s core strength lies in its established market presence and widespread consumer familiarity.
• Patent expirations have led to increased competition, squeezing profit margins.
• Growth prospects depend heavily on expanding into emerging markets and innovation in formulations.
• Regulatory risks require ongoing compliance and safety profiling.
• The OTC analgesic segment remains stable, with moderate growth driven by consumer health trends.

FAQs

1. What are the primary growth drivers for MEDIPREN?

   Rising healthcare access in emerging markets and steady demand for OTC analgesics.

2. How does patent expiration affect MEDIPREN’s profitability?

   It enables generic competition, reducing prices and profit margins.

3. What are the regulatory hurdles for new formulations?

   New formulations require safety and efficacy data approval, which can extend time-to-market and increase costs.

4. Is MEDIPREN vulnerable to regulatory safety warnings?

   Yes. Safety concerns, especially hepatotoxicity at high doses, can impact sales and regulatory status.

5. What strategic options exist for pharmaceutical companies owning MEDIPREN?

   Formulation innovation, geographic expansion, and cost efficiencies to maintain competitive advantage.

---

References

1. Grand View Research. (2022). Analgesics Market Size, Share & Trends Analysis [Data set]. https://www.grandviewresearch.com/industry-analysis/analgesics-market

2. U.S. Food and Drug Administration. (2021). Acetaminophen Safety Guidelines. https://www.fda.gov

3. World Health Organization. (2020). Global Overview of OTC Drugs. https://www.who.int

4. Statista. (2022). Over-the-Counter (OTC) Market Revenue. https://www.statista.com

5. European Medicines Agency. (2021). Safety Communication on Acetaminophen. https://www.ema.europa.eu